Summary
Pfizer Inc. reported a decrease in total revenues for the third quarter of 2025, down 6% to $16.7 billion, primarily due to lower sales of Paxlovid and Comirnaty. This decline was partially offset by growth in key products like Eliquis and the Vyndaqel family. Net income attributable to Pfizer Inc. common shareholders for the quarter was $3.54 billion, a decrease from $4.47 billion in the prior year's third quarter, resulting in diluted EPS of $0.62 compared to $0.78. For the nine-month period ended September 28, 2025, total revenues also saw a slight decrease of 2% to $45.0 billion. Net income attributable to common shareholders increased to $9.42 billion from $7.62 billion in the prior year's nine-month period, with diluted EPS rising to $1.65 from $1.34. The company highlighted significant investments in R&D, including a $1.35 billion charge for an in-licensing agreement with 3SBio. Pfizer is actively managing its cost base through realignment and manufacturing optimization programs, aiming for significant net cost savings. The company also announced a proposed acquisition of Metsera for approximately $4.9 billion, subject to closing conditions.
Financial Highlights
53 data points| Revenue | $16.65B |
| Cost of Revenue | $4.17B |
| Gross Profit | $12.48B |
| SG&A Expenses | $3.19B |
| Interest Expense | $652.00M |
| Net Income | $3.54B |
| EPS (Basic) | $0.62 |
| EPS (Diluted) | $0.62 |
| Shares Outstanding (Basic) | 5.68B |
| Shares Outstanding (Diluted) | 5.71B |
Key Highlights
- 1Total revenues decreased by 6% to $16.7 billion in Q3 2025, primarily due to lower Paxlovid and Comirnaty sales, partially offset by growth in Eliquis and Vyndaqel family.
- 2Net income attributable to common shareholders decreased to $3.54 billion ($0.62/share) in Q3 2025, down from $4.47 billion ($0.78/share) in Q3 2024.
- 3For the first nine months of 2025, net income attributable to common shareholders increased to $9.42 billion ($1.65/share) from $7.62 billion ($1.34/share) in the same period of 2024.
- 4Acquired in-process R&D expenses significantly increased due to a $1.35 billion charge for an in-licensing agreement with 3SBio.
- 5Pfizer announced a proposed acquisition of Metsera for approximately $4.9 billion to bolster its obesity and cardiometabolic disease pipeline.
- 6Cost of sales decreased by 21% in Q3 2025, largely due to a favorable sales mix and lower amortization, contributing to improved gross margins.
- 7The company is executing cost realignment and manufacturing optimization programs expected to yield substantial net cost savings.